EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieBeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Long‐term effects of ipragliflozin and pioglitazone on metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow‐up of a randomized, 24 week, active‐controlled trial

Daisuke Ito iD, Satoshi Shimizu, Akifumi Haisa, Shinnosuke Yanagisawa, Kazuyuki Inoue, Daigo Saito, Takashi Sumita, Morifumi Yanagisawa, Yoshihito Uchida iD, Kouichi Inukai, Akira Shimada iD

Journal of Diabetes Investigation · 2024

DOI: 10.1111/jdi.14246 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Diabetes Investigation, 2024. Verfasst von Daisuke Ito und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Diabetes, Saitama Medical University, Saitama, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Pioglitazone, Thiophenes, Glucosides. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims/Introduction We conducted a 5 year post‐trial monitoring study of our previous randomized 24 week, open‐label, active‐controlled trial that showed beneficial effects of ipragliflozin on metabolic dysfunction‐associated steatotic liver disease (MASLD), identical to those of pioglitazone. Materials and Methods In our previous trial, 66 patients with MASLD and type 2 diabetes were randomly assigned to receive either ipragliflozin ( n = 32) or pioglitazone ( n = 34). Upon its conclusion, 61 patients were monitored for 5 years for outcome measures of MASLD, glycemic, and metabolic parameters. Differences between the two groups were analyzed at baseline, 24 weeks, and 5 years; changes in outcome measures from baseline were also evaluated.

Results

At 5 years, the mean liver‐to‐spleen attenuation ratio increased by 0.20 (from 0.78 ± 0.24 to 0.98 ± 0.20) in the ipragliflozin group and by 0.26 (from 0.76 ± 0.26 to 1.02 ± 0.20) in the pioglitazone group ( P = 0.363). Similarly, ipragliflozin and pioglitazone significantly improved serum aminotransferase, HbA1c, and fasting plasma glucose levels over 5 years. In the ipragliflozin group, significant reductions in body weight and visceral fat area observed at 24 weeks were sustained throughout the 5 years (−4.0%, P = 0.0075 and −7.6%, P = 0.045, respectively). Moreover, ipragliflozin significantly reduced the values of fibrosis markers (serum ferritin and FIB‐4 index), was well tolerated, and had a higher continuation rate for 5 years compared with pioglitazone.

Conclusions

Ipragliflozin and pioglitazone improved MASLD and glycemic parameters over 5 years. In the ipragliflozin group, significant reductions in body weight and visceral fat mass persisted for 5 years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2PioglitazoneThiophenesGlucosidesHumansMaleFemaleMiddle AgedFollow-Up StudiesHypoglycemic AgentsAgedBlood GlucoseTreatment OutcomeFatty LiverSodium-Glucose Transporter 2 Inhibitors

Stichwörter der Autor:innen

Metabolic dysfunction‐associated steatotic liver diseaseNon‐alcoholic fatty liver diseaseSodium‐glucose cotransporter 2 inhibitors

Substanzen

ipragliflozinPioglitazoneThiophenesGlucosidesHypoglycemic AgentsBlood GlucoseSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Endocrinology and Diabetes, Saitama Medical University, Saitama, Japan.
  • Department of Internal Medicine, Ogawa Red Cross Hospital, Saitama, Japan.
  • Satsuki Medical Clinic, Saitama, Japan.
  • Department of Gastroenterology and Hepatology, Saitama Medical University, Saitama, Japan.
  • Department of Diabetes and Endocrinology, Higashiyamato Hospital, Tokyo, Japan.

ORCID-Profile: Daisuke Ito, Yoshihito Uchida, Akira Shimada

Zitieren

APA

Ito, D., Shimizu, S., Haisa, A., Yanagisawa, S., Inoue, K., Saito, D., Sumita, T., Yanagisawa, M., Uchida, Y., Inukai, K., & Shimada, A. (2024). Long‐term effects of ipragliflozin and pioglitazone on metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow‐up of a randomized, 24 week, active‐controlled trial. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.14246

Vancouver

Ito D, Shimizu S, Haisa A, Yanagisawa S, Inoue K, Saito D, et al. Long‐term effects of ipragliflozin and pioglitazone on metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow‐up of a randomized, 24 week, active‐controlled trial. Journal of Diabetes Investigation. 2024. doi:10.1111/jdi.14246

BibTeX
@article{Ito2024,
  author = {Ito, Daisuke and Shimizu, Satoshi and Haisa, Akifumi and Yanagisawa, Shinnosuke and Inoue, Kazuyuki and Saito, Daigo and Sumita, Takashi and Yanagisawa, Morifumi and Uchida, Yoshihito and Inukai, Kouichi and Shimada, Akira},
  title = {Long‐term effects of ipragliflozin and pioglitazone on metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow‐up of a randomized, 24 week, active‐controlled trial},
  journal = {Journal of Diabetes Investigation},
  year = {2024},
  doi = {10.1111/jdi.14246}
}
Kostenlos starten →